Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria - -- Bezuclastinib demonstrated a powerful effect on mast cell burden with 91% of patients achieving ≥50% reduction in variant allele frequency and 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates - -- Bezuclastinib continues to demonstrate a favorable safet